Company Directory / Biotechnology

Amicus Therapeutics logo

Public · NASDAQ:FOLDFor profitBiotechnologyPrinceton, NJ, United States

Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.

Founded
2002
24 years ago
Staff
501-1000
612 on LinkedIn
Followers
48k
on LinkedIn
Funding
$2.4B
as listed, USD

We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. Our company was founded by an entrepreneur who embarked on a life-long journey to transform the lives of those living with devastating conditions when two of his… Read all

We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases. Amicus is the Latin word for friend. This name signifies our collaborative approach to developing medicines by incorporating the patient perspective every step of the way. Our company was founded by an entrepreneur who embarked on a life-long journey to transform the lives of those living with devastating conditions when two of his children were diagnosed with a rare disease. That spirit of empathy, compassion, and tenacity permeates our culture and influences all aspects of our approach to advancing cutting-edge technologies. Building on our core beliefs, our mission-focused behaviors help us define and shape our culture; drive performance and innovation; inform development and growth; and attract, energize, and retain the right talent. By championing mission-dedication, innovation, performance, and integrity, we are united by our passion for making a difference and committed to pushing ideas as far and as fast as possible. Our global footprint spans over 20 countries, including our global headquarters in Princeton, NJ and international headquarters in Marlow, UK. Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, The Netherlands, and Spain. More information about Amicus and our career opportunities can be found at www.amicusrx.com.

Set against six million companies

Size

1-1011-5051-100101-250251-500501-10001k-5k5k-10k10k+

501-1000 people: larger than 95% of companies with a size listed. 612 people list it on LinkedIn.

Age

200219002026

24 years old.

Reach

Website ranked #2,757,644 in the world for traffic, about 6k visits a month. 48,329 followers on LinkedIn.

What it does

BiotechnologyHealth CarePharmaceuticalTherapeutics

Funding, as listed

$2.4B raised in total

  • Rounds20
  • LatestPost ipo debt, Oct 2023
  • Latest amountUSD 30,000,000
  • Investors18, 9 leading

What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.

FoundersJohn Crowley
Acquisitions made3

Every detail we hold

Everything the source datasets list about Amicus Therapeutics, field by field. Contact details are held but never shown.

The company

Name
Amicus Therapeutics
Type
For profit
Status
Public · NASDAQ:FOLD
Founded
2002
Founders
John Crowley
Industry
Biotechnology
Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics

Where

City
Princeton
Region
NJ
Country
United States
Markets
Greater New York Area, East Coast, Northeastern US

Size and reach

Staff band
501-1000
People on LinkedIn
612
LinkedIn followers
48,329
Web traffic rank
#2,757,644
Monthly web visits
6,290

Funding, as listed

Total
$2,430,652,943 USD
Rounds
20
Latest round
Post ipo debt
Latest round date
Oct 2023
Latest amount
30,000,000 USD
Investors
18
Lead investors
9
Stock listing
NASDAQ:FOLD
Listing status
public

Corporate family

Acquisitions made
3

About this record

Sources
Crunchbase, LinkedIn
Last imported
Sept 2026

Growth, as the source summarises it

Amicus Therapeutics opened a new global headquarters in Princeton. The company received the Prix Galien U.K. Award for Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) as Best Pharmaceutical Product. An analyst maintained a Buy rating on Amicus Therapeutics' stock amid competition.

Summaries written by the source dataset, not by us, and not checked.

Companies like it

Biotechnology in United States.

See all in the directory →

From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 1,637,054 companies in United States and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.